<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038437</url>
  </required_header>
  <id_info>
    <org_study_id>CPX351-103</org_study_id>
    <nct_id>NCT04038437</nct_id>
  </id_info>
  <brief_title>A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML</brief_title>
  <official_title>A Phase 1b Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML Who Are Unfit for Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine&#xD;
      the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly&#xD;
      diagnosed AML who are unfit for intensive chemotherapy (ICT). This study will comprise 2&#xD;
      phases: a Dose Escalation Phase and an Expansion Phase, in which all subjects will receive a&#xD;
      combination of CPX-351 and venetoclax.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) as determined by the specified dose escalation</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>The MTD as determined by the specified dose escalation and MTD algorithm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AE) and Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>The safety and tolerability of CPX-351 and venetoclax when given in combination based on the incidence of AEs and DLTs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have achieved CR, CRi, PR, and CRc (CR + CRi)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Proportion of subjects who have achieved CR, CRi, PR, and CRc (CR + CRi) by the completion of treatment (up to 4 cycles of therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have achieved ORR</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Proportion of subjects who have achieved ORR, defined as best response (CR + CRi + PR) by the completion of treatment (up to 4 cycles of therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have achieved CR / CRi with MRD status</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Proportion of subjects who have achieved CR / CRi with MRD status (negative / positive) by the completion of treatment (up to 4 cycles of therapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>Area under the plasma concentration time curve from time 0 to the time of the next dosing during a 48 hour interval at the steady-state of CPX-351 PK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-Life (t½)</measure>
    <time_frame>Up to 30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>CPX-351 and Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPX-351 and Venetoclax will be administered over 28 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>CPX-351 will be administered on Days 1 and 3 of each cycle</description>
    <arm_group_label>CPX-351 and Venetoclax</arm_group_label>
    <other_name>Vyxeos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax will be adminstered on Days 2 to 21 of each cycle</description>
    <arm_group_label>CPX-351 and Venetoclax</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Subject must have newly diagnosed AML with histological confirmation by World Health&#xD;
        Organization (WHO) criteria.&#xD;
&#xD;
        Definition of subjects who are unfit for ICT:&#xD;
&#xD;
        • Each subject must meet the following criteria characterizing him / her as unfit to&#xD;
        receive ICT within 21 days prior to the first day of therapy to be enrolled in the study:&#xD;
&#xD;
          -  ≥ 75 years of age OR&#xD;
&#xD;
          -  ≥ 18 to 74 years of age and fulfilling at least 1 criteria associated with lack of&#xD;
             fitness for ICT as follows:&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 to 3;&#xD;
&#xD;
               -  Cardiac history of Congestive Heart Failure (CHF) requiring treatment or left&#xD;
                  ventricular ejection fraction (LVEF) ≤ 50%.&#xD;
&#xD;
               -  Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) ≤ 65% or Forced&#xD;
                  Expiratory Volume in 1 second (FEV1) ≤ 65%;&#xD;
&#xD;
               -  Creatinine clearance (CrCl) ≥ 30 mL/min to &lt; 45 mL/min calculated by the&#xD;
                  Cockcroft-Gault formula;&#xD;
&#xD;
               -  Moderate hepatic impairment with total bilirubin &gt; 1.5 to ≤ 3.0 × Upper Limit of&#xD;
                  Normal (ULN);&#xD;
&#xD;
               -  Other comorbidity that the physician judges to be incompatible with conventional&#xD;
                  intensive chemotherapy which must be reviewed and approved by the study medical&#xD;
                  monitor before study enrollment.&#xD;
&#xD;
        In addition, all subjects must meet the following criteria:&#xD;
&#xD;
          -  If the subject is ≥ 75 years of age, then ECOG Performance Status must be 0-2.&#xD;
&#xD;
          -  Subject must have adequate renal function as demonstrated by a CrCl ≥ 30 mL/min&#xD;
             (calculated by the Cockcroft Gault formula or measured by 24-hour urine collection).&#xD;
&#xD;
          -  Subject must have adequate liver function as demonstrated by:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤ 3.0 × ULN*&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤ 3.0 × ULN*&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 × ULN (subjects who are &lt; 75 years of age may have bilirubin of ≤&#xD;
                  3.0 × ULN)* *Unless considered to be due to leukemic organ involvement.&#xD;
&#xD;
          -  Female subjects must be either postmenopausal defined as:&#xD;
&#xD;
               -  Age &gt; 55 years with no menses for ≥ 2 years without an alternative medical cause.&#xD;
&#xD;
               -  OR&#xD;
&#xD;
               -  Age ≤ 55 years with no menses for ≥ 12 months without an alternative medical&#xD;
                  cause AND a follicle-stimulating hormone level &gt; 40 IU/L;&#xD;
&#xD;
               -  OR&#xD;
&#xD;
               -  Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or&#xD;
                  hysterectomy); OR&#xD;
&#xD;
          -  A woman of childbearing potential practicing at least 1 protocol specified method of&#xD;
             birth control starting at Study Day 1 through at least 6 months after the last dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  A woman of childbearing potential must have negative results for pregnancy test&#xD;
             performed:&#xD;
&#xD;
               -  At Pretreatment with a serum sample obtained within 14 days prior to the first&#xD;
                  study treatment administration, and&#xD;
&#xD;
               -  Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been &gt; 7&#xD;
                  days since obtaining the serum pregnancy test results.&#xD;
&#xD;
               -  Subjects with borderline pregnancy tests at Pretreatment must have a serum&#xD;
                  pregnancy test ≥ 3 days later to document continued lack of a positive result.&#xD;
&#xD;
          -  Male subjects who are sexually active, must agree, from Study Day 1 through at least 6&#xD;
             months after the last dose of study treatment, to practice protocol specified methods&#xD;
             of contraception. Male subjects must agree to refrain from sperm donation from initial&#xD;
             study treatment administration through at least 6 months after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Subject must have a white blood cell count ≤ 25 × 109/L. (Note: subjects who have&#xD;
             undergone hydroxyurea administration or leukapheresis for therapeutic cytoreduction&#xD;
             will be considered eligible).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has ECOG Performance Status &gt; 3, regardless of age.&#xD;
&#xD;
          -  Subject has known Human Immunodeficiency Virus (HIV) infection (due to potential&#xD;
             drug-drug interactions between antiretroviral medications and venetoclax). HIV testing&#xD;
             will be performed at Pretreatment, if required per local guidelines or institutional&#xD;
             standards.&#xD;
&#xD;
          -  Subject has consumed grapefruit, grapefruit products, Seville oranges (including&#xD;
             marmalade containing Seville oranges) or Star fruit within 3 days prior to the&#xD;
             initiation of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Trial Disclosure &amp; Transparency</last_name>
    <phone>2159707145</phone>
    <email>ClinicalTrialDisclosure@JazzPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber/ Brigham &amp; Women's Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUSC Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CPX-351</keyword>
  <keyword>Vyxeos</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Unfit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

